GlassScriptPhysician profile
William S Goldstein
NPI 1437159738
$1,277.53
in general payments reported to CMS, 2019-2025
14 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $74.23 · 2021: $21.91 · 2022: $235 · 2023: $423 · 2024: $84.95 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $479.02 | 2019-2025 | Clareon, Centurion, Rocklatan |
| New World Medical,INC. | $365.79 | 2019-2024 | Kahook Dual Blade, Clearpath, Streamline |
| Glaukos Corporation | $168.49 | 2019-2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.59 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $30.04 | 2023 | Cequa |
| Abbvie INC. | $28.89 | 2023 | |
| Rxsight INC | $27.23 | 2022 | |
| Bausch & Lomb Americas INC. | $19.62 | 2023 | Vyzulta |
| Novartis Pharmaceuticals Corporation | $18.96 | 2020 | |
| Shire North American Group INC | $18.58 | 2019 | |
| Allergan, INC. | $17.74 | 2019 | |
| Lkc Technologies, INC. | $17.64 | 2025 | |
| Ocular Therapeutix, INC. | $17.09 | 2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $15.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.